Proactive’s CEO Sessions next month feature three pharma & biotech companies developing potentially life-changing medical treatments and two exploration companies with projects that have game-changing potential.
All five companies will present at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.
Zelda is making significant progress in its business growth strategy with a focus on developing drugs to support clinical decision making for individual patients.
Recent developments include a heads of agreement (HoA) with medicinal cannabis company Ilera Healthcare to explore collaborative opportunities and being granted a new patent covering a novel method to predict patient disease-free survival.
The range of commercialisation opportunities with US-based Ilera include licensing of Zelda products, co-development and data sharing.
Zelda’s Australian patent details a method for detecting levels of expression of a novel receptor complex containing proteins HER2 and CB2.
HER2 is a recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.
Invitrocue is a leading healthcare bio-analytic solutions provider that recently signed an agreement with the Shanghai Institute of Biochemistry and Cell Biology for the development of new breast cancer models for its proprietary Onco-PDO test.
The Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients.
Oventus is a medical device company commercialising a unique treatment platform for the treatment of sleep apnea and snoring.
Early this year the company recently launched a lightweight sleep apnea treatment appliance in Australia, the nylon-made O2Vent Optima device.
This is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and improves the effectiveness of oral appliance therapy.
Optima incorporates Brisbane-based Oventus’ proprietary airway technology and is compatible with the Oventus ExVent valve technology which will also be launched this year.
Xanadu Mines recently completed an open pit scoping study at the Kharmagtai Copper-Gold Project in Mongolia, which is in the same region as Rio Tinto plc’s (LON:RIO) massive Oyu Tolgoi Copper-Gold Project.
This study confirmed the viability of near-surface copper and gold mineralisation as well as the company’s strategy to explore for high-value large copper porphyry systems in the area.
It has identified opportunities for further upside from extending the life of the planned open pit mine, assessing higher-grade underground options and evaluating oxide gold potential near-surface at several locations.
Metallurgical test work is in progress to refine the recoveries of copper and gold reporting to concentrate.
Infinity Lithium is seeking to develop its 75%-owned San Jose Lithium Project in Spain and produce battery-grade lithium hydroxide.
The company is on-track to complete an updated pre-feasibility study (PFS) for the project in June or July this year.
Stage I test work has been completed focusing on metallurgical test work designed to confirm previous upgrade factors from the November 2018 scoping study, which valued the project at up to US$1.017 billion.
As a result of this work, suitable amounts of concentrate have been produced for stage II hydrometallurgical test work.
This is designed to develop the sulphate-roast-water-leach (SRWL) flowsheet to a PFS standard.
After stage II, the leach solution produced will move to stage III, the final stage, where through a process of purification and crystallisation lithium hydroxide will be produced.
Register for the CEO Sessions today